<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42191">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557100</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-567</org_study_id>
    <nct_id>NCT02557100</nct_id>
  </id_info>
  <brief_title>Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine changes in immune cells and proteins in response to
      treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus
      adalimumab, both given in combination with methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of abatacept based on changes to autoantibody levels</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of abatacept based on changes to cytokines</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of abatacept based on changes to percentages of immune cell subsets</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of abatacept based on changes to activation states of immune cell subsets</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept in combination with methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abatacept subcutaneous (SC) injection, 125 mg, weekly for 24 weeks. Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX &lt; 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses. Open-label Abatacept subcutaneous (SC) injection, 125 mg, weekly and maintain the enrollment dose of MTX unless toxicity or intolerability occurs during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab in combination with methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab SC injection, 40 mg, once every two weeks for 24 weeks, Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX &lt; 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses. Open-label Abatacept subcutaneous (SC) injection, 125 mg, weekly and maintain the enrollment dose of MTX unless toxicity or intolerability occurs during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <arm_group_label>Abatacept in combination with methotrexate</arm_group_label>
    <arm_group_label>Adalimumab in combination with methotrexate</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Adalimumab in combination with methotrexate</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Abatacept in combination with methotrexate</arm_group_label>
    <arm_group_label>Adalimumab in combination with methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Symptoms of RA for no more than 12 months prior to enrollment

          -  Meet American College of Rheumatology/European League against Rheumatism (ACR/EULAR)
             2010 criteria for classification of RA

          -  Treated with Methotrexate (MTX) for at least 12 weeks prior to randomization with a
             stable oral dose for at least 4 weeks, Subjects must randomize on the maximum
             tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week),
             dose of MTX &lt; 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to
             higher doses

          -  At least 3 tender &amp; 3 swollen joints

          -  Anti-cyclic citrullinated peptide (CCP) &gt; 3X the upper limit of normal and positive
             rheumatoid factor

        Exclusion Criteria:

          -  History of other autoimmune diseases (eg, psoriasis, systemic lupus, erythematosus,
             etc)

          -  Prior use of non-biologic therapy other than methotrexate

          -  Prior use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs
             (DMARD) therapy

          -  Subjects with chronic or recent acute serious infection

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uab Arthritis Clinical Intervention Program</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Curtis, Site 0020</last_name>
      <phone>205-934-9843</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates Of North Alabama, P.C.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Shergy, Site 0017</last_name>
      <phone>256-704-7098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical And Translational Research Center Of Alabama, Pc</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Jones, Site 0012</last_name>
      <phone>205-464-4711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research Pllc</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Tesser, Site 0015</last_name>
      <phone>602-386-4969</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research Pllc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nehad Soloman, Site 0016</last_name>
      <phone>623-512-4802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Hospital Yorba Linda</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Pang, Site 0001</last_name>
      <phone>714-992-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Greenwald, Site 0005</last_name>
      <phone>760-341-6800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado School Of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Striebich, Site 0007</last_name>
      <phone>303-724-7607</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Washington Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pragya Singh, Site 0010</last_name>
      <phone>202-994-8567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Quinones, Site 0019</last_name>
      <phone>202-865-3326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology &amp; Immunology Specialists</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Valenzuela, Site 0002</last_name>
      <phone>954-476-2338</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marietta Rheumatology</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Abubaker, Site 0013</last_name>
      <phone>770-372-3962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center For Rheumatology And Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Demarco, Site 0014</last_name>
      <phone>301-942-6610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Birbara, Site 0021</last_name>
      <phone>508-755-0201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aa Mrc Llc</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>98439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Karrar, Site 0011</last_name>
      <phone>810-237-1125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Rigby, Site 0004</last_name>
      <phone>603-650-4717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (Ohsu)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cong-Qiu Chu, Site 0018</last_name>
      <phone>503-494-5571</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Kivitz, Site 0009</last_name>
      <phone>814-693-0300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Aelion, Site 0003</last_name>
      <phone>731-633-0119</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic Of Northern Virginia, P.C.</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Kempf, Site 0006</last_name>
      <phone>703-525-3069</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Anil K Gupta Med Prof Corp</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Gupta, Site 0025</last_name>
      <phone>416-741-1500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut De Rhumatologie De Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boulos Haraoui, Site 0023</last_name>
      <phone>514-523-8603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre De Recherche Musculo-Squelettique</name>
      <address>
        <city>Trois-rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Morin, Site 0024</last_name>
      <phone>819-370-1301</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>September 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
